Thanks.
I've previously expressed my views about Campbell's reliability.
I'd rather not watch another 28 min.
Could you say which study he refers to, or where in the talk it's discussed, please?
Jonathan
Thanks.
I ask again, what has it to do with the PB vaccine?Audax67 wrote: ↑19 Apr 2021, 1:38pm Link to adenovirus paper. Enjoy:
https://ashpublications.org/blood/artic ... he-role-of
Looking back, probably nothing. I had gained the impression that the PB used adenovirus encapsulation whereas it appears to use a synthetic(?) lipid shell. I've seen elsewhere, though, that clotting stats post-AZ and post-PB are similar.mjr wrote: ↑19 Apr 2021, 2:44pmI ask again, what has it to do with the PB vaccine?Audax67 wrote: ↑19 Apr 2021, 1:38pm Link to adenovirus paper. Enjoy:
https://ashpublications.org/blood/artic ... he-role-of
The researcher involved has also said that even though there have been some successful vaccines using the adenovirus technology (e.g. Ebola), that this is the first time it has been used on a very large scale. They have also said that the risk remains low, and within acceptable levels.translated from forskning.no* wrote: Gunnveig Grødeland believes that the most important thing in the Norwegian study is that it finds a difference when it compares the vaccine from Pfizer with the AstraZeneca vaccine.
The vaccines from AstraZeneca, Johnson & Johnson, and the Sputnik vaccine are based on the same vaccine technology, as forskning.no has previously explained.
- The results support what we know that the serious side effects are related to vaccines based on adenoviral vectors.
- This strengthens the observations that these side effects will not be associated with mRNA vaccines.
See "Mitigating inequalities" in the current prioritisation:
That's rather like the UK where we seem to have online central booking, GP booking and telephone booking all operating with different requirements and options. And then there are occasional reports of vaccinators roaming nearby streets trying to recruit volunteers to use up the last few doses of thawed Pfizer after Did Not Attends.francovendee wrote: ↑21 Apr 2021, 8:03am Strange system is in place that you can get it done three way:
Thanks JD but I've seen that before and seems to be only a recommendation that BAME get a higher priority and also mentions that because they have more representation in at risk groups which got a higher priority at the roll out.Jdsk wrote: ↑21 Apr 2021, 10:50amSee "Mitigating inequalities" in the current prioritisation:
https://www.gov.uk/government/publicati ... ember-2020
https://www.gov.uk/government/publicati ... ementation
(And if I could give a more helpful answer about what's happening in practice I would!)
Jonathan
So EU wants to sue AstraZeneca for not supplying a vaccine the EU doesn't want, which Macron says doesn't work and of which the EU already has huge stockpiles which haven't been used?EU starts legal case against AstraZeneca over vaccine delays
The European commission has initiated a legal case against AstraZeneca over its “complete failure” to meet delivery and contractual agreements for its vaccine, Ireland’s health minister Stephen Donnelly has said. See earlier post for more details.
If that report is right the litigant would be the European Commission, not the European Union. And the Commission isn't responsible for the vaccination programmes of Member States because that would be... the Member States.philg wrote: ↑22 Apr 2021, 2:59pm Guardian todaySo EU wants to sue AstraZeneca for not supplying a vaccine the EU doesn't want, which Macron says doesn't work and of which the EU already has huge stockpiles which haven't been used?EU starts legal case against AstraZeneca over vaccine delays
The European commission has initiated a legal case against AstraZeneca over its “complete failure” to meet delivery and contractual agreements for its vaccine, Ireland’s health minister Stephen Donnelly has said. See earlier post for more details.
The EU does want it: even at the peak of caution, almost half of countries were still using it, including some offering to take France's unused doses if they want.
Moderna's already approved, the Janssen one-shot is just being deployed, there's probably others coming. I don't think Pfizer-BioNTech have the stranglehold suggested.Reported elsewhere that the EU are considering not using AZ for future vaccine contracts - well that should give them good leverage in price negotiations with Pfizer then